Overview

A Study of Type-1 Polarized Dendritic Cell (αDC1) Vaccine in Combination With Tumor-Selective Chemokine Modulation (Interferon-α2b, Rintatolimod, and Celecoxib) in Subjects With Chemo-Refractory Metastatic Colorectal Cancer

Status:
Withdrawn

Trial end date:
2018-12-01

Target enrollment:

Participant gender:

Summary

The investigators hypothesize that the treatment of metastatic colorectal cancer (mCRC) patients with the combination of alpha-type-1-polarized dendritic cell (αDC1) vaccines and tumor-selective chemokine modulation (CKM) will promote the infiltration of vaccination-induced CD8+ CTLs to tumor lesions and subsequently tumor regression with improved patient survival.

Phase:

Phase 2

Details

Lead Sponsor:

Pawel Kalinski

Treatments:

Celecoxib
Interferons
Poly I-C
poly(I).poly(c12,U)
Vaccines